2019
DOI: 10.1136/esmoopen-2018-000479
|View full text |Cite
|
Sign up to set email alerts
|

Olaratumab administered in two cases of phyllodes tumour of the breast: end of the beginning?

Abstract: Phyllodes tumours of the breast are rare mesenchymal tumours with differential malignant potential. Treatment of choice is radical excision with negative margins. Radiation therapy has shown controversial results in small series. Chemotherapy in the adjuvant setting still remains a matter of debate. Doxorubicin-based chemotherapy is recommended for breast sarcomas’ first-line treatment. Herein we present two cases of breast phyllodes tumour treated with the recent combination of doxorubicin and olaratumab.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
7
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 9 publications
(7 citation statements)
references
References 25 publications
0
7
0
Order By: Relevance
“…We have recently published the poor outcome of Olaratumab administration to two patients with phyllodes tumor of the breast. 38 Herein, we report the potentially beneficial addition of Olaratumab to the 1st line treatment of metastatic hEHE.…”
Section: Discussionmentioning
confidence: 99%
“…We have recently published the poor outcome of Olaratumab administration to two patients with phyllodes tumor of the breast. 38 Herein, we report the potentially beneficial addition of Olaratumab to the 1st line treatment of metastatic hEHE.…”
Section: Discussionmentioning
confidence: 99%
“…Radiotherapy remains a controversial topic but can be applied in local recurrences. Chemotherapy is reserved for malignant phyllodes with distant metastases that should be treated as a soft tissue sarcoma [ 3 , 30 ]. Mastectomy, performed in various fashions (simple, radical, radical extended, etc.)…”
Section: ⧉ Discussionmentioning
confidence: 99%
“…Margin-negative resection combined with adjuvant radiotherapy is very effective for local control and prevention of recurrence [6]. Adjuvant chemotherapy is not the standard care since it is of controversial value for malignant phyllodes tumors, yet some institutions support doxorubicin-based adjuvant chemotherapy for rst-line treatment of breast sarcomas, especially with > 5.0 cm large high-risk tumors [22][23]. During postoperative follow-up, no local recurrence or distant metastasis were found.…”
Section: Discussionmentioning
confidence: 99%